- Home
- BOKF vs MDGL Comparison
BOKF vs MDGL Comparison
Compare BOKF & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOKF
- MDGL
- Stock Information
- Founded
- BOKF 1910
- MDGL 2011
- Country
- BOKF United States
- MDGL United States
- Employees
- BOKF N/A
- MDGL N/A
- Industry
- BOKF Major Banks
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- BOKF Finance
- MDGL Health Care
- Exchange
- BOKF Nasdaq
- MDGL Nasdaq
- Market Cap
- BOKF 6.7B
- MDGL 7.4B
- IPO Year
- BOKF N/A
- MDGL N/A
- Fundamental
- Price
- BOKF $114.31
- MDGL $317.09
- Analyst Decision
- BOKF Buy
- MDGL Buy
- Analyst Count
- BOKF 12
- MDGL 14
- Target Price
- BOKF $109.55
- MDGL $347.33
- AVG Volume (30 Days)
- BOKF 153.2K
- MDGL 654.8K
- Earning Date
- BOKF 10-21-2024
- MDGL 10-31-2024
- Dividend Yield
- BOKF 2.00%
- MDGL N/A
- EPS Growth
- BOKF N/A
- MDGL N/A
- EPS
- BOKF 7.27
- MDGL N/A
- Revenue
- BOKF $2,004,867,000.00
- MDGL $76,813,000.00
- Revenue This Year
- BOKF N/A
- MDGL N/A
- Revenue Next Year
- BOKF $6.17
- MDGL $193.46
- P/E Ratio
- BOKF $15.71
- MDGL N/A
- Revenue Growth
- BOKF N/A
- MDGL N/A
- 52 Week Low
- BOKF $69.76
- MDGL $168.25
- 52 Week High
- BOKF $119.52
- MDGL $368.29
- Technical
- Relative Strength Index (RSI)
- BOKF 56.36
- MDGL 61.98
- Support Level
- BOKF $113.26
- MDGL $272.72
- Resistance Level
- BOKF $118.80
- MDGL $342.58
- Average True Range (ATR)
- BOKF 2.80
- MDGL 23.09
- MACD
- BOKF 0.04
- MDGL -2.66
- Stochastic Oscillator
- BOKF 67.84
- MDGL 51.44
About BOKF BOK Financial Corporation
BOK Financial Corp is the largest financial institution in Oklahoma and it provides a comprehensive range of nationally competitive financial products and services. Its operating segments consist of commercial banking, consumer banking, and wealth management. The company has various products and services including cash management services, loans and deposits, fiduciary and insurance services, mortgage banking and brokerage and trading services. It generates maximum revenue from the commercial banking segment. Its commercial banking segment includes lending, treasury and cash management services, and customer risk management products to small businesses, middle market, and larger commercial customers.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.